$0.5751
+0.03
(+4.58%)▲
Live
Revenue is up for the last 2 quarters, 113.0K → 114.0K (in $), with an average increase of 0.9% per quarter
Netprofit is up for the last 3 quarters, -66.36M → -11.75M (in $), with an average increase of 148.3% per quarter
In the last 1 year, 10x Genomics Inc has given 43.0% return, outperforming this stock by 120.6%
5.1%
Downside
Day's Volatility :16.08%
Upside
11.57%
9.45%
Downside
52 Weeks Volatility :80.97%
Upside
78.99%
Period | Akili Inc | Index (Russel 2000) |
---|---|---|
3 Months | -52.18% | 0.0% |
6 Months | -66.26% | 2.0% |
1 Year | -78.85% | 5.3% |
3 Years | -94.5% | 19.9% |
Market Capitalization | 77.4M |
Book Value | $1.06 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 0.02 |
PE Ratio | 49.5 |
Wall Street Target Price | 4.0 |
Profit Margin | 940.71% |
Operating Margin TTM | -19205.95% |
Return On Assets TTM | -60.57% |
Return On Equity TTM | 7.28% |
Revenue TTM | 420.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 78.10000000000001% |
Gross Profit TTM | -118.0K |
EBITDA | -80.4M |
Diluted Eps TTM | 0.02 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.77 |
EPS Estimate Next Year | -0.58 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 595.53%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 20.0M | - |
Net Income | -20.6M | - |
Net Profit Margin | -103.24% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.9M | ↓ 80.29% |
Net Income | -25.6M | ↑ 24.29% |
Net Profit Margin | -651.08% | ↓ 547.84% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 323.0K | - |
Net Income | -19.0M | - |
Net Profit Margin | -5.9K% | - |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 64.0K | - |
Net Income | -1.7M | ↓ 58.48% |
Net Profit Margin | -2.7K% | - |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 82.0K | ↑ 28.13% |
Net Income | 53.2M | ↓ 3170.04% |
Net Profit Margin | 64.9K% | ↑ 67631.4% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 241.0K | ↑ 193.9% |
Net Income | -66.4M | ↓ 224.66% |
Net Profit Margin | -27.5K% | ↓ 92459.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 113.0K | ↓ 53.11% |
Net Income | -20.7M | ↓ 68.79% |
Net Profit Margin | -18.3K% | ↑ 9208.92% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 114.0K | ↑ 0.88% |
Net Income | -11.8M | ↓ 43.22% |
Net Profit Margin | -10.3K% | ↑ 8013.41% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 43.5M | - |
Total Liabilities | 125.8M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 20.2M | ↓ 53.65% |
Total Liabilities | 125.1M | ↓ 0.56% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 251.2M | ↑ 1144.68% |
Total Liabilities | 9.7M | ↓ 92.25% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 144.6M | ↓ 42.45% |
Total Liabilities | 33.9M | ↑ 249.62% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 250.8M | ↓ 0.17% |
Total Liabilities | 13.4M | ↑ 38.78% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 251.0M | ↑ 0.11% |
Total Liabilities | 15.5M | ↑ 14.91% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 165.0M | ↓ 34.26% |
Total Liabilities | 41.2M | ↑ 166.37% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 144.6M | ↓ 12.41% |
Total Liabilities | 33.9M | ↓ 17.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 124.6M | ↓ 13.81% |
Total Liabilities | 32.2M | ↓ 5.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 111.5M | ↓ 10.54% |
Total Liabilities | 28.5M | ↓ 11.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.4M | - |
Investing Cash Flow | -461.0K | - |
Financing Cash Flow | 4.9M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.6M | ↓ 16.44% |
Investing Cash Flow | -116.0K | ↓ 74.84% |
Financing Cash Flow | 2.0M | ↓ 59.54% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -54.0M | ↑ 119.88% |
Investing Cash Flow | -492.0K | ↑ 324.14% |
Financing Cash Flow | 112.8M | ↑ 5547.9% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -83.5M | ↑ 54.72% |
Investing Cash Flow | -81.2M | ↑ 16407.32% |
Financing Cash Flow | 141.9M | ↑ 25.78% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -358.2K | ↓ 98.02% |
Investing Cash Flow | -15.0M | ↑ 124766.67% |
Financing Cash Flow | 64.0K | ↓ 45.76% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -174.9K | ↓ 51.16% |
Investing Cash Flow | 10.0M | ↓ 166.72% |
Financing Cash Flow | 250.0K | ↑ 290.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -60.9M | ↑ 34698.07% |
Investing Cash Flow | -61.6M | ↓ 716.66% |
Financing Cash Flow | -110.0M | ↓ 44084.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.1M | ↓ 63.68% |
Investing Cash Flow | -14.6M | ↓ 76.35% |
Financing Cash Flow | 251.6M | ↓ 328.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.1M | ↓ 13.62% |
Investing Cash Flow | 52.9M | ↓ 462.9% |
Financing Cash Flow | -45.0K | ↓ 100.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.6M | ↓ 39.33% |
Investing Cash Flow | -19.4M | ↓ 136.6% |
Financing Cash Flow | -647.0K | ↑ 1337.78% |
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Akili Inc | -42.12% | -66.26% | -78.85% | -94.5% | -94.5% |
![]() R1 Rcm Inc | -4.59% | 7.01% | -15.37% | -3.35% | 59.47% |
![]() 10x Genomics Inc | -13.66% | -16.9% | 43.83% | -66.73% | -21.61% |
![]() Veeva Systems Inc. | 7.41% | 14.42% | 28.58% | -25.85% | 94.67% |
![]() Ge Healthcare Technologies Inc. | -6.21% | -15.78% | 6.35% | 6.35% | 6.35% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Akili Inc | 49.5 | 49.5 | NA | -0.77 | 0.07 | -0.61 | 0.0 | 1.06 |
![]() R1 Rcm Inc | 128.18 | NA | 0.77 | 0.06 | -0.02 | 0.02 | 0.0 | 6.55 |
![]() 10x Genomics Inc | NA | NA | NA | -1.69 | -0.22 | -0.11 | 0.0 | 6.76 |
![]() Veeva Systems Inc. | 61.02 | 61.02 | 1.27 | 4.18 | 0.15 | 0.05 | 0.0 | 25.85 |
![]() Ge Healthcare Technologies Inc. | 19.51 | 19.51 | NA | 3.8 | 0.15 | 0.06 | 0.0 | 15.62 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Akili Inc | Buy | $77.4M | -94.5% | 49.5 | 940.71% |
![]() R1 Rcm Inc | Buy | $6.3B | 59.47% | 128.18 | -3.09% |
![]() 10x Genomics Inc | Buy | $6.3B | -21.61% | NA | -30.31% |
![]() Veeva Systems Inc. | Buy | $32.6B | 94.67% | 61.02 | 24.2% |
![]() Ge Healthcare Technologies Inc. | Buy | $31.5B | 6.35% | 19.51 | 9.62% |
Social Capital Group LLC
Temasek Holdings Ltd.
Neuberger Berman Group LLC
Baillie Gifford & Co Limited.
Suvretta Capital Management, LLC
Comprehensive Financial Management LLC
Organization | Akili Inc |
Employees | 111 |
CEO | Dr. Walter Edward Martucci Ph.D. |
Industry | Healthcare |
Revance Therapeutics Inc
$0.58
+4.58%
Xeris Biopharma Holdings Inc
$0.58
+4.58%
Avanos Medical, Inc.
$0.58
+4.58%
Collegium Pharmaceutical Inc
$0.58
+4.58%
Airsculpt Technologies
$0.58
+4.58%
Lemaitre Vascular Inc
$0.58
+4.58%
Axogen, Inc.
$0.58
+4.58%
Corbus Pharmaceuticals Holdings, Inc.
$0.58
+4.58%
Precigen Inc
$0.58
+4.58%